Business Context and Reporting Period
This Form 8-K filing by CareDx, Inc. covers the reporting period of December 12, 2018. The report addresses corporate governance changes specifically regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the resignation of Amy Abernethy, M.D., Ph.D., from the Board of Directors. Her departure is effective January 31, 2019. The filing explicitly states that this resignation is not the result of any disagreement with the Company or matters relating to its operations, policies, or practices.
Outlook and Management Commentary
Dr. Abernethy is resigning to accept an appointment as Principal Deputy Commissioner of the U.S. Food and Drug Administration. The Company issued a press release on December 17, 2018, announcing this departure, which is attached as Exhibit 99.1. No financial guidance, risk factors, or unusual items are discussed in this specific filing.
Key Facts for Investor Verification
- Dr. Amy Abernethy will resign from the CareDx Board effective January 31, 2019.
- The resignation is voluntary and driven by a new government appointment, not internal disputes.
- The Company is classified as an emerging growth company.
- Investors should review the attached press release (Exhibit 99.1) for further details on the transition.